TORONTO — Clinical trials have shown that many automated insulin delivery (AID) systems are safe and effective for nonpregnant patients with type 1 diabetes (T1D). They are associated with improved ...

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod®brand of products, has shared new clinical evidence related to the ...

The FDA cleared an automated insulin delivery system for use by pregnant women with type 1 diabetes, according to an industry ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Children with type 1 diabetes can benefit from ...

The FDA has cleared Tandem’s Control-IQ technology as the first ever AID specifically for use in pregnancies complicated by ...

This sub-analysis is the first study to evaluate AID outcomes for people with type 2 diabetes using the Center for Medicare and Medicaid Services (CMS) criteria for insulin pump coverage. SAN ...

New research from Washington State University in collaboration with five other institutions suggests that automated insulin delivery (AID) systems are safe and effective for use by older adults with ...

Outcomes from EVOLUTION 2 study include 68% time in range with no boluses Diverse multicenter feasibility study highlights the promise of future Omnipod innovation to address unmet needs, improve ...

Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, ...